Brief: Innovation Pharmaceuticals Brilacidin Received By U.S. Regional Biocontainment Laboratory Testing Against Coronavirus
09/03/2020 13:45
March 9 (Reuters) - Innovation Pharmaceuticals Inc
IPIX.PK :
* INNOVATION PHARMACEUTICALS BRILACIDIN RECEIVED BY U.S.
REGIONAL
BIOCONTAINMENT LABORATORY; TESTING AGAINST CORONAVIRUS
(COVID-19)
* INNOVATION PHARMACEUTICALS INC - COMPANY ANTICIPATES
CONFIRMATION OF TESTING SCHEDULE AS WELL AS PROCEDURES FOR
STUDIES LATER THIS WEEK
Source text for Eikon: ID:nGNXvWXZK
Further company coverage: IPIX.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Innovation Pharmaceuticals
See all newsBrief: Innovation Pharmaceuticals Announces New Milestone At Beamed On Track To File 510(K) Submission To FDA In Q2 2024
Brief: Innovation Pharmaceuticals Provides Update On US Patent Applications Covering Use Of Brilacidin In Inflammatory Bowel Diseases, Coronaviruses And Fungal Diseases
Brief: Innovation Pharma Reports Enrollment In Phase 2 Trial Of Brilacidin For COVID-19 Tops 70%
Brief: Innovation Pharma Surpasses 50% Enrollment In Phase 2 Clinical Trial Of Brilacidin For COVID-19
Brief: Innovation Pharma Completes Interim Safety Data Review